Skip to search formSkip to main contentSkip to account menu

ABT-263

Known as: BcI-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT 263 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

navitoclax

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Highly Cited
2013
Highly Cited
2013
BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins.
Determining mechanistic details about how drugs kill cancer cells is critical for predicting which cancers will respond to given… 
2012
2012
Doubts concerning functional endothelial nitric oxide synthase in human erythrocytes.
To the editor: Nitric oxide (NO) is involved in the modulation of multiple physiologic functions. NO is produced from L-Arg by… 
Highly Cited
2012
Highly Cited
2012
Distinct Regulation of Cytoplasmic Calcium Signals and Cell Death Pathways by Different Plasma Membrane Calcium ATPase Isoforms in MDA-MB-231 Breast Cancer Cells*
Background: The roles of different PMCA isoforms are not fully understood particularly in cell death. Results: PMCA4 and PMCA1… 
2011
2011
ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
The tyrosine kinase Src plays an important role in the development of anoikis resistance in lung adenocarcinomas. Several… 
Review
2010
Review
2010
Therapy of chronic lymphocytic leukaemia.
2010
2010
Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Abstract 3904 Background: Navitoclax (ABT-263), a novel, orally bioavailable, small molecule, binds with high affinity (Ki ≤1nM… 
2009
2009
Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.
Abstract 1711 Poster Board I-737 Bcl-2 family members are associated with tumor initiation and drug resistance, and are… 
2008
2008
An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Abstract 883 ABT-263, a novel orally bioavailable BH3 mimetic, binds with high affinity (K i ≤ 1nM) and inhibits multiple… 
2008
2008
HPLC-MS/MS determination of a hardly soluble drug in human urine through drug-albumin binding assisted dissolution.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)